Maze Therapeutics (NASDAQ:MAZE) Reaches New 1-Year High – Still a Buy?

Maze Therapeutics, Inc. (NASDAQ:MAZE) shares reached a new 52-week high during trading on Tuesday . The stock traded as high as $47.47 and last traded at $47.47, with a volume of 28606 shares traded. The stock had previously closed at $43.58.

Analysts Set New Price Targets

A number of analysts recently issued reports on MAZE shares. Raymond James Financial assumed coverage on Maze Therapeutics in a research report on Thursday, November 13th. They issued an “outperform” rating and a $48.00 price target for the company. HC Wainwright restated a “buy” rating on shares of Maze Therapeutics in a report on Wednesday, January 28th. Wedbush lifted their price target on shares of Maze Therapeutics from $35.00 to $36.00 and gave the stock an “outperform” rating in a research note on Friday, November 7th. Guggenheim reissued a “buy” rating and issued a $46.00 price objective on shares of Maze Therapeutics in a research report on Friday, December 19th. Finally, BTIG Research raised their price objective on shares of Maze Therapeutics from $37.00 to $46.00 and gave the stock a “buy” rating in a research note on Friday, January 16th. Three equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $44.50.

Maze Therapeutics Stock Performance

The company has a market cap of $2.11 billion and a P/E ratio of -2.10. The business’s fifty day moving average is $41.48 and its two-hundred day moving average is $29.71.

Maze Therapeutics (NASDAQ:MAZE) last issued its earnings results on Thursday, November 6th. The company reported ($0.66) EPS for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.08.

Insiders Place Their Bets

In other news, insider Atul Dandekar sold 72,400 shares of the firm’s stock in a transaction on Monday, December 29th. The stock was sold at an average price of $40.56, for a total transaction of $2,936,544.00. Following the transaction, the insider owned 10,503 shares in the company, valued at approximately $426,001.68. This trade represents a 87.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Amy Bachrodt sold 10,000 shares of Maze Therapeutics stock in a transaction dated Monday, December 29th. The shares were sold at an average price of $40.58, for a total value of $405,800.00. Following the completion of the sale, the senior vice president owned 12,965 shares of the company’s stock, valued at $526,119.70. The trade was a 43.54% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 200,000 shares of company stock worth $8,254,792 in the last ninety days.

Institutional Investors Weigh In On Maze Therapeutics

Several large investors have recently modified their holdings of the business. Ameritas Investment Partners Inc. raised its stake in Maze Therapeutics by 82.6% in the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after buying an additional 738 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in shares of Maze Therapeutics in the 4th quarter valued at $39,000. Legal & General Group Plc raised its position in shares of Maze Therapeutics by 23.0% in the 3rd quarter. Legal & General Group Plc now owns 5,219 shares of the company’s stock worth $135,000 after acquiring an additional 977 shares in the last quarter. Bank of America Corp DE lifted its stake in shares of Maze Therapeutics by 33.6% during the 2nd quarter. Bank of America Corp DE now owns 5,782 shares of the company’s stock worth $71,000 after purchasing an additional 1,455 shares during the last quarter. Finally, Russell Investments Group Ltd. boosted its position in Maze Therapeutics by 947.8% during the third quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock valued at $49,000 after purchasing an additional 1,725 shares in the last quarter.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.